![2-Methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-(4-morpholinyl)-1H-benzimidazole-4-carbo…](https://static.cymitquimica.com/products/3D/img/FM102909.png "Click to enlarge")
2-Methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid
CAS: 1372540-25-4
Ref. 3D-FM102909
| 5mg | Discontinued | ||
| 10mg | Discontinued | ||
| 25mg | Discontinued |
Product Information
Name:
2-Methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid
Description:
2-Methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid (BIC) is a strain that is categorized as a cancer drug. It has been synthesized in the laboratory and has been shown to bind to the bRaf protein, inhibiting its activity. BIC is also known as a stereoisomer because it has two different forms, L and D. The symbol for this drug is "BIC". This drug discriminates between healthy cells and cancer cells by selectively targeting those with mutated bRaf proteins. The parameter of this drug that is quantized is its effect on cancer cells. BIC's virulent effects may be due to its ability to inhibit the synthesis rate of antibodies in the body.
Notice:
Our products are intended for lab use only. For any other use, please contact us.
Brand:
Biosynth
Long term storage:
Notes:
Chemical properties
Molecular weight:
433.42 g/mol
Formula:
C22H22F3N3O3
Purity:
Min. 95%
MDL:
Melting point:
Boiling point:
Flash point:
Density:
Concentration:
EINECS:
Merck:
HS code:
